jpm_asset_mgmt
  • Funds

    Fund Explorer

    • SICAVs
    • Exchange-Traded Funds
    • Liquidity Funds

    Fund Documents

    • Regulatory Documents
  • Investment Strategies

    Investment Options

    • Alternatives
    • Beta Strategies
    • Equities
    • Fixed Income
    • Global Liquidity
    • Multi-Asset Solutions

    Capabilities & Solutions

    • ETFs
    • Pension Strategy & Analytics
    • Global Insurance Solutions
    • Outsourced CIO
    • Sustainable Investing
  • Insights

    Market Insights

    • Market Insights Overview
    • Eye on the Market
    • Guide to the Markets
    • Guide to Alternatives
    • Market Updates

    Portfolio Insights

    • Portfolio Insights Overview
    • Alternatives
    • Asset Class Views
    • Currency
    • Equity
    • ETF Perspectives
    • Fixed Income
    • Long-Term Capital Market Assumptions
    • Sustainable Investing Insights
  • Resources
    • Center for Investment Excellence Podcasts
    • Insights App
    • Library
    • Webcasts
  • About us
  • Contact Us
Skip to main content
  • English
  • Role
  • Country
  • Client Reporting
Search
Menu
CLOSE
Search
  1. Home
  2. Insights
  3. Market Insights
  4. Eye on the Market
  5. Coronavirus research

  • Share
  • LinkedIn Twitter Facebook
  • Email
  • Print
  • Actions
  • LinkedIn Twitter Facebook
    Email Print

Coronavirus (COVID-19) research

January 2021

Michael Cembalest

This compilation includes all of our research to-date on the coronavirus. High frequency charts on infection, mortality, economic and market data are updated as data becomes available, usually on a daily basis.

What’s new: US economy showing some signs of slowing after COVID surge (Section 1); Tracking the COVID surge in the US and Europe (Section 2); Vaccination update by country and US state (Section 3); Tracking ICU spare capacity by state (Section 2 and Section 5).

To hear more of Michael Cembalest’s thoughts on global markets and the economy, explore previous versions of Eye on the Market:

READ MORE BY MICHAEL CEMBALEST

Access Michael Cembalest’s COVID Charts of the Week:

VIEW NOW

Our research to-date on the coronavirus:


1. US spending, mobility, and production tracker ›
2. COVID global infection, hospitalization and mortality tracker ›
3. COVID vaccination update and drug development ›
4. COVID: testing for the virus, testing for antibodies and T-cell immunity and survivor impacts ›
5. Detailed virus reports by state ›

1. US spending, mobility, and production tracker

  • High frequency recovery tracking (mobility, manufacturing, retail, air travel, geolocation, oil, hotels, housing, etc.)
  • Real time credit and debit spending data

READ MORE


2. COVID global infection, hospitalization and mortality tracker

  • Global COVID infection snapshot by US state and country (trends, declines from peak levels)
  • US hotspot tracking: infections, hospitalizations, mortality, testing and doctor visits
  • Infection and mortality time series by country
  • How lethal is COVID, and for whom?

READ MORE


3. COVID vaccination update and drug development

  • Vaccination update by country and US state
  • Vaccine coverage timelines by country for vulnerable and total populations
  • How mRNA vaccines and vecor vaccines work
  • Pfizer, Moderna and Oxford/Astrazeneca Phase III results
  • Vaccine production, distribution and acceptance challenges
  • The latest news on anti-virals, monoclonal antibodies, convalescent plasma and corticosteroids

READ MORE


4. COVID: testing for the virus and for antibodies, T-cell immune memory and survivor impacts 

  • How virus testing and antibody testing work 
  • Pre-existing T-cell immune memory and COVID
  • The latest seroprevalence tests in US states
  • The issue of falling antibody levels in convalescing patients
  • COVID health impacts on survivors

READ MORE


5. Detailed virus reports by state 

  • One-page reports on each state with charts on infections, hospitalizations, mortality, testing levels, positive test rates, hospital ICU capacity rates and doctor visit indicators

READ MORE

This compilation incorporates research and feedback from the Johns Hopkins University Center for Health Security, Harvard Medical School, the University of Toronto Dalla Lana School of Public Health, Washington University Biomedical Sciences Department, the La Jolla Institute for Immunology, the Imperial College of London Department of Infectious Disease Epidemiology and the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.


0903c02a8283f910

Listen and Subscribe

 

Listen on Apple Podcasts ›

Subscribe to RSS Feed ›

   

 

Get the latest commentaries in your inbox ›

Follow Michael Cembalest on LinkedIn ›

Markets Volatility Eye on the Market
J.P. Morgan Asset Management

  • About us
  • Investment stewardship
  • Privacy policy
  • Cookie policy
  • Binding corporate rules
  • Sitemap
Opens LinkedIn site in new window
J.P. Morgan

  • J.P. Morgan
  • JPMorgan Chase
  • Chase

READ IMPORTANT LEGAL INFORMATION. CLICK HERE >

The value of investments may go down as well as up and investors may not get back the full amount invested.

Copyright 2021 JPMorgan Chase & Co. All rights reserved.